StockData
Cullinan Therapeutics, Inc. logo

Cullinan Therapeutics, Inc. (CGEM) stock

CGEMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 7/30
$9.01−0.27 (-2.86%)

Close on Nov 18, 2026Market cap $579.84MP/E –Yield –

Cullinan Therapeutics gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

No gross profit figures for Cullinan Therapeutics

Cullinan Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Cullinan Therapeutics figures

See a number that looks wrong?